Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Demeter

Showing results (41-50 of 89) with videos related to

Pageof 9
Sort By:
The Journal of Biological Chemistry|December 15, 1987
Detection of conformational changes in human chorionic gonadotropin upon binding to rat gonadal receptorsW R Moyle, A Pressey, D Dean-Emig, et al.
HIV Clinical Trials|November 3, 2011
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 studyMary Albrecht, A Lisa Mukherjee, Camlin Tierney, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2006
HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responsesJennifer E Snyder-Cappione, Anagha A Divekar, Genny M Maupin, et al.
Journal of Virology|June 11, 1999
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesP Gerondelis, R H Archer, C Palaniappan, et al.
The Journal of Infectious Diseases|July 18, 2006
Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New YorkAmneris E Luque, Musaret Jabeen, Susan Messing, et al.
The Journal of Infectious Diseases|March 5, 2004
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudineCarrie Dykes, Joe Najjar, Ronald J Bosch, et al.
Journal of Virology|August 23, 2000
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell cultureR H Archer, C Dykes, P Gerondelis, et al.
Genes & Development|July 1, 1992
Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFFS C Dollard, J L Wilson, L M Demeter, et al.
Therapeutic Drug Monitoring|March 19, 2013
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146Xinyan Zhang, Camlin Tierney, Mary Albrecht, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1995
Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1L M Frenkel, L E Wagner, L M Demeter, et al.
Pageof 9

Showing results (41-50 of 89) with videos related to

Sort By:
Pageof 9
The Journal of Biological Chemistry|December 15, 1987
Detection of conformational changes in human chorionic gonadotropin upon binding to rat gonadal receptorsW R Moyle, A Pressey, D Dean-Emig, et al.
HIV Clinical Trials|November 3, 2011
A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 studyMary Albrecht, A Lisa Mukherjee, Camlin Tierney, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 4, 2006
HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responsesJennifer E Snyder-Cappione, Anagha A Divekar, Genny M Maupin, et al.
Journal of Virology|June 11, 1999
The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activitiesP Gerondelis, R H Archer, C Palaniappan, et al.
The Journal of Infectious Diseases|July 18, 2006
Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New YorkAmneris E Luque, Musaret Jabeen, Susan Messing, et al.
The Journal of Infectious Diseases|March 5, 2004
Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudineCarrie Dykes, Joe Najjar, Ronald J Bosch, et al.
Journal of Virology|August 23, 2000
Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell cultureR H Archer, C Dykes, P Gerondelis, et al.
Genes & Development|July 1, 1992
Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFFS C Dollard, J L Wilson, L M Demeter, et al.
Therapeutic Drug Monitoring|March 19, 2013
Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146Xinyan Zhang, Camlin Tierney, Mary Albrecht, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 1, 1995
Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1L M Frenkel, L E Wagner, L M Demeter, et al.
Pageof 9